Here are three things to know.
1. Zilretta is administered as an intra-articular injection.
2. The non-opioid drug is intended to provide pain relief for patients with moderate to severe OA knee pain over a 12-week period.
3. Flexion expects Zilretta to hit the market by the end of the month.
More articles on supply chain:
FDA commissioner: High drug prices are a ‘public health concern the FDA should address’
Judge ruling allows drug ‘price gouging’ law to take effect in Maryland
Rite Aid names former Walgreens executive as president, COO
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
